News | August 11, 2022
Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022
The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Subscribe To Our Newsletter & Stay Updated
